Skip to main content

Table 3 Characteristics of PAD patients and non-PAD patients

From: High prevalence of peripheral arterial disease (PAD) in incident hemodialysis patients: screening by ankle-brachial index (ABI) and skin perfusion pressure (SPP) measurement

  Peripheral arterial disease P
+
N 45 140  
Age (years) 72 (64–81) 69 (59–84) 0.055
Male n (%) 33 (73.3) 97 (69.3) 0.605
Smoking n (%) 17 (37.8) 58 (41.4) 0.694
Hypertension n (%) 40 (88.9) 108 (77.1) 0.087
Dyslipidemia n (%) 24 (53.3) 55 (39.3) 0.056
Diabetes mellitus n (%) 29 (64.4) 71 (50.7) 0.108
Ischemic heart disease n (%) 27 (60.0) 47 (33.6) 0.001
Stroke n (%) 10 (22.2) 17 (12.1) 0.095
ARB n (%) 19 (42.2) 55 (39.3) 0.646
Statin n (%) 19 (42.2) 41 (29.3) 0.086
Hemoglobin (g/dL) 8.7 (7.3–9.8) 8.3 (7.0–9.2) 0.079
ABI 0.92 (0.73–1.08) 1.22 (1.12–1.29) < 0.0001
SPP 47 (34–71) 75 (69–86) < 0.0001
Blood glucose (mg/dL) 124 (108–181) 127 (98–160) 0.406
Albumin (g/dL) 3.2 (2.8–3.6) 3.3 (2.8–3.6) 0.637
Ca (mg/dL) 7.8 (7.2–8.4) 7.7 (7.0–8.3) 0.486
P (mg/dL) 5.9 (4.7–7.1) 6.2 (5.0–7.4) 0.453
Total cholesterol (mg/dL) 176 (153–224) 158 (135–192) 0.015
Triglyceride (mg/dL) 98 (71–136) 101 (76–147) 0.821
HDL-C (mg/dL) 44.8 (34.6–55.2) 39.1 (31.0–48.6) 0.067
LDL-C (mg/dL) 106 (74–124) 83 (68.3–104.8) 0.025
CRP (mg/dL) 0.74 (0.615–2.815) 0.47 (0.120–3.730) 0.653
 Cilstazol, n (%) 6 (13.3%) 5 (3.5%) 0.026
 Sarpogrelate, n (%) 0 (0%) 1 (0.7%) 0.455
 Aspirin, n (%) 26 (48.9%) 22 (22.6%) 0.0002
 Prostaglandin analogue, n (%) 9 (20.5%) 8 (5.7%) 0.006
  1. Data are presented as median (interquartile range)
  2. PAD peripheral arterial disease, ARB angiotensin II receptor blocker, Ca calcium, P phosphate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, CRP C-reactive protein